International Assets Investment Management LLC Acquires 2,798 Shares of CVS Health Corporation (NYSE:CVS)

International Assets Investment Management LLC boosted its holdings in CVS Health Corporation (NYSE:CVS) by 25.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,995 shares of the pharmacy operator’s stock after purchasing an additional 2,798 shares during the period. International Assets Investment Management LLC’s holdings in CVS Health were worth $948,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CVS. McIlrath & Eck LLC grew its holdings in shares of CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 174 shares during the last quarter. Coppell Advisory Solutions LLC grew its holdings in CVS Health by 17.3% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator’s stock worth $56,000 after acquiring an additional 189 shares during the last quarter. EagleClaw Capital Managment LLC increased its position in shares of CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock valued at $275,000 after acquiring an additional 200 shares during the period. Angeles Investment Advisors LLC raised its stake in shares of CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after acquiring an additional 204 shares during the last quarter. Finally, Beck Mack & Oliver LLC boosted its holdings in shares of CVS Health by 1.1% during the fourth quarter. Beck Mack & Oliver LLC now owns 20,425 shares of the pharmacy operator’s stock worth $917,000 after purchasing an additional 232 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Price Performance

CVS opened at $66.44 on Thursday. The firm has a market cap of $84.05 billion, a PE ratio of 15.86, a P/E/G ratio of 0.97 and a beta of 0.56. The stock has a 50-day moving average price of $64.81 and a 200-day moving average price of $60.62. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $72.51. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.31 earnings per share. Sell-side analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Guy P. Sansone bought 1,570 shares of the business’s stock in a transaction on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the transaction, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.22% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on CVS shares. Truist Financial upped their price target on CVS Health from $82.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, May 12th. Cowen reaffirmed a “buy” rating on shares of CVS Health in a research note on Monday, May 5th. UBS Group boosted their price objective on shares of CVS Health from $67.00 to $71.00 and gave the company a “neutral” rating in a research report on Friday, May 2nd. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a research report on Tuesday, April 15th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.